ClinicalTrials.gg
Not yet recruitingNCT07723911Updated Jul 23, 2026

A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL

A Phase 3 interventional study of BLB101 for Injection and Blinatumomab for Injection in Precursor B-cell Acute Lymphoblastic Leukemia, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
212
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

A Randomized, Double-Blind, Positive-Controlled, Multicenter Clinical Study to Compare the Similarities in Pharmacokinetics, Efficacy, Safety and Immunogenicity Between Injectable BLB101 and Blincyto® in Adult Participants with R/R CD19+ B-ALL. Provide evidence for the approval and marketing of the drug for its targeted indication.

Primary Objectives:

  1. To compare the pharmacokinetic similarity between Injectable BLB101 and Blincyto® in participants with R/R B-ALL.
  2. To compare the efficacy similarity between Injectable BLB101 and Blincyto® in participants with R/R B-ALL.

Primary Endpoints:

  1. Css and area AUC0-24,d1 of Injectable BLB101 versus Blincyto® in participants with R/R B-ALL.
  2. CR/CRh within the first two induction cycles of treatment with Injectable BLB101 and Blincyto® in participants with R/R B-ALL, as assessed by the IRC per the response criteria for ALL.

This study plans to enroll approximately 212 participants, who will be randomized at a 1:1 ratio into the following two groups:

Test group: BLB101 for injection Control group: Blinatumomab for injection (Blincyto®) A stratified block randomization method will be adopted. The randomization stratification factors are as follows:a) Creatinine clearance (≤90 mL/min vs >90 mL/min);b) Baseline leukemic cell proportion (≤50% vs >50%);c) Relapsed/refractory status (first relapse vs ≥2 relapses or refractory disease).

For each participant, the overall study procedure is outlined as follows: Participants will receive treatment with either BLB101 for injection or Blincyto®. Each treatment cycle consists of 6 weeks, including 4 weeks of dosing followed by a 2-week treatment-free interval. Each participant is required to complete the first 2 induction treatment cycles (i.e., an induction treatment period of up to 12 weeks), after which the participant will be considered to have fulfilled the primary study objectives.

Read the detailed description

A Randomized, Double-Blind, Positive-Controlled, Multicenter Clinical Study to Compare the Similarities in Pharmacokinetics, Efficacy, Safety and Immunogenicity Between Injectable BLB101 and Blincyto® in Adult Participants with R/R CD19+ B-ALL. Provide evidence for the approval and marketing of the drug for its targeted indication.

Primary Objectives:

  1. To compare the pharmacokinetic similarity between Injectable BLB101 and Blincyto® in participants with R/R B-ALL.
  2. To compare the efficacy similarity between Injectable BLB101 and Blincyto® in participants with R/R B-ALL.

Primary Endpoints:

  1. Css and area AUC0-24,d1 of Injectable BLB101 versus Blincyto® in participants with R/R B-ALL.
  2. CR/CRh within the first two induction cycles of treatment with Injectable BLB101 and Blincyto® in participants with R/R B-ALL, as assessed by the IRC per the response criteria for ALL
02

Conditions studied

  • Precursor B-cell Acute Lymphoblastic Leukemia
03

In context

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

38 studies on the registry are indexed under Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; 16 are open to participants now.

This study's planned enrollment of 212 is above the median of 44 across 33 interventional studies indexed under Precursor B-Cell Lymphoblastic Leukemia-Lymphoma.

Browse Precursor B-Cell Lymphoblastic Leukemia-Lymphoma studies →

Lead sponsor

Institute of Hematology & Blood Diseases Hospital, China is the lead sponsor of 414 studies on the registry; 292 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following inclusion criteria to be included in this study:

  1. Before the trial began, the trial details were known, and the participant understood and voluntarily signed the Form (ICF);
  2. Age ≥ 18 years old;
  3. Confirmed as Philadelphia chromosome (Ph) negative and CD19 positive B-ALL (must meet: ① Through morphological and local flow cytometry immunophenotype assessment, there are expressed CD19 primitive immature cells in peripheral blood or bone marrow, confirming the current state of relapse, and there are relevant medical records to support; ② The proportion of primitive cells in the bone marrow is greater than 5% (measured by morphology); ③ Chromosome karyotype analysis or FISH analysis or PCR or NGS confirms Ph-negative), the Ph status needs to be reconfirmed before enrollment;
  4. ≤ 2 points;
  5. The number of previous treatment lines is 1 to 2, and it meets the definition of relapse or refractory (any of the following conditions can be included in the group: ① Late relapse: Reversal after achieving remission with previous treatment and duration ≥ 12 months; ② Early relapse: Remission achieved with previous treatment and duration \< 12 months; ③ Refractory: Failure to achieve remission during the first induction or salvage treatment; ④ Recurrence after transplantation: Recurrence at any time after hematopoietic stem cell transplantation);
  6. Weight ≥ 45 kg;
  7. Expected survival period ≥ 3 months;
  8. Organ function requirements: Liver and kidney function: /AST ≤ 3 times the (ULN), total ≤ 1.5 × ULN; rate ≥ 60 mL/min; Cardiac function: (LVEF) ≥ 50%, no severe arrhythmia;
  9. Participants need to have recovered to ≤ Grade 1 toxicity from previous treatments (according to V6.0 standards), excluding hematological toxicity;
  10. Participants need to meet the from the first administration of anti-tumor treatment: a) At least 2 weeks after the end of cytotoxic chemotherapy drugs treatment; b) At least 5 half-lives after non-cytotoxic drugs (if the duration of 5 half-lives exceeds 4 weeks, the washout period is still counted as 4 weeks), for drugs with an unclear half-life, it is counted as more than 4 weeks; c) At least 2 weeks after anti-tumor traditional Chinese medicine treatment; d) At least 3 months after CAR-T treatment; e) At least 5 half-lives after antibody drugs and antibody conjugate drugs (ADC); (if the duration of 5 half-lives exceeds 3 months, the washout period is still counted as 3 months);
  11. According to the investigator's judgment, the participant's compliance can reach understanding and following the plan for visits, treatment, laboratory tests, and other research procedures, and is expected to receive the study drug for ≥ 1 cycle;
  12. For female participants with reproductive capacity: Agree to take effective measures from the start of signing the informed consent form until 6 months after the last administration of the trial drug, and agree not to donate eggs. For male participants: Agree to take effective contraceptive measures from the start of signing the informed consent form until 6 months after the last administration of the trial drug, and agree not to donate sperm. -

Exclusion criteria

Exclusion Criteria:

Participants who meet any of the following criteria are not eligible to be included in this study:

  1. Participants with negative CD19 in ALL;
  2. Participants with Ph-positive ALL or mixed phenotype;
  3. Pregnant or lactating women;
  4. Active central nervous system (CNS) leukemia (cerebrospinal fluid white blood cells ≥ 5/μL and leukemia cells are observed); those with a history of CNS disease who have received effective treatment and achieved remission are excluded;
  5. Participants with Burkitt lymphoma/leukemia;
  6. Participants with isolated extramedullary disease recurrence and active ALL in the testicles;
  7. Participants who have received targeted CD19 anti-tumor therapy before and have a proportion of CD19-positive leukemia cells \< 50%;
  8. Participants who have received at least 28 days of targeted CD19 bispecific antibody treatment and have been ineffective (ineffectiveness is defined as the failure to achieve CR or CRh or CRi or MLFS in the efficacy evaluation);
  9. Participants who have received at least 1 time of targeted CD19 CAR-T infusion and have been ineffective (ineffectiveness is defined as the failure to achieve CR or CRh or CRi or MLFS in the efficacy evaluation);
  10. Participants who have received targeted CD19 bispecific antibody treatment and have achieved CR or CRh or CRi or MLFS but have within ≤ 6 months;
  11. Participants who have received targeted CD19 CAR-T treatment and have achieved CR or CRh or CRi or MLFS but have relapsed within ≤ 12 months;
  12. Participants who have received HSCT within 6 weeks before the first administration or have received allogeneic HSCT within 3 months before the first administration;
  13. Any active acute (GvHD) grade 2-4 (according to the Glucksberg standard), or active chronic GvHD requiring systemic treatment;
  14. Any systemic treatment for GVHD within 2 weeks before the first administration;
  15. Participants with positive antibody; participants with active infection: positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and peripheral blood HBV DNA above the ; positive for antibody and positive for HCV RNA in peripheral blood;
  16. Participants have active infections (including bacterial, viral, and fungal infections) that require systemic intravenous antibiotics treatment as judged by the investigator to have clinical significance;
  17. Participants with significant active cardiovascular disease within the past 6 months, including but not limited to the following conditions: ≥ III grade heart failure according to the (NYHA) definition; angina pectoris, unstable angina pectoris, myocardial infarction requiring surgical treatment; uncontrolled hypertension (i.e., systolic blood pressure ≥ 160 mmHg, diastolic blood pressure ≥ 90 mmHg) after treatment; arrhythmia not controlled; echocardiography-measured resting left ventricular function less than 50%; : male > 450 msec, female > 470 msec (according to the QTcF formula), or receiving known drugs that prolong QT/QTc interval, or having other factors that may prolong QTc interval; or for those whose QT interval remains > 450 msec after treatment for QT interval prolongation;
  18. Participants with a history of other within the past 5 years, but excluding cured cutaneous basal cell carcinoma, localized skin squamous cell carcinoma, cervical carcinoma in situ, or breast carcinoma in situ;
  19. Participants with uncontrolled third space effusion (such as pleural effusion, ascites, pericardial effusion), requiring repeated drainage;
  20. Participants who have had interstitial lung disease (ILD)/interstitial pneumonia in the past or currently, and deemed by the investigator not suitable for inclusion in this study;
  21. Have a clear allergy to immunoglobulin or injectable belinotuzumab monoclonal antibody and its other components;
  22. Within the 4 weeks prior to the administration of this study, the participant has participated in other clinical trials of intervention drugs or medical devices, or is currently receiving treatment in other clinical trials (excluding non-interventional studies);
  23. Circumstances deemed unsuitable for participation in the trial by the investigator (such as, the investigator believes it may pose risks to the participant's safety or interfere with the evaluation, procedures, or completion of any other medical history or having any other clinically significant disease at present (excluding those listed above).
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
212 participants (estimated)

Study arms

  • Active comparator
    BLB101 for Injection

    BLB101 for injection administered via intravenous infusion at a dose of 9μg/d or 28 μg/d. One treatment cycle consists of 6 weeks, including 4 weeks of dosing followed by a 2-week treatment-free interval.Participants weighing ≥45kg received fixed dosing: In Induction Cycle 1: 9μg/d on Days1-7, followed by 28μg/d on Days 8-28, then a 14-day treatment-free period.In Induction Cycle 2: 28μg/d on Days 1-28, followed by a 14-day treatment-free period.For participants weighing \<45kg, doses were calculated by body surface area (BSA): Induction Cycle 1: 5μg/m²/d (max 9μg/d) on Days1-7, 15μg/m²/d (max 28μg/d) on Days8-28, followed by a 14-day treatment-free period; Induction Cycle 2: 15μg/m²/d (max 28μg/d) on Days1-28, followed by a 14-day treatment-free period.

    Drug: BLB101 for Injection

  • Active comparator
    Blinatumomab for Injection

    Blinatumomab for injection administered via intravenous infusion at a dose of 9μg/d or 28 μg/d. One treatment cycle consists of 6 weeks, including 4 weeks of dosing followed by a 2-week treatment-free interval.Participants weighing ≥45kg received fixed dosing: In Induction Cycle 1: 9μg/d on Days1-7, followed by 28μg/d on Days 8-28, then a 14-day treatment-free period.In Induction Cycle 2: 28μg/d on Days 1-28, followed by a 14-day treatment-free period.For participants weighing \<45kg, doses were calculated by body surface area (BSA): Induction Cycle 1: 5μg/m²/d (max 9μg/d) on Days1-7, 15μg/m²/d (max 28μg/d) on Days8-28, followed by a 14-day treatment-free period; Induction Cycle 2: 15μg/m²/d (max 28μg/d) on Days1-28, followed by a 14-day treatment-free period.

    Drug: Blinatumomab for Injection

Interventions

  • DrugBLB101 for Injection

    BLB101 for Injection;Administration route: Intravenous infusion; Dose: 9 μg/day or 28 μg/day;Drug administration schedule: Each 6-week period constitutes a treatment cycle. During each cycle, the drug is administered for 4 weeks and then the drug is withheld for 2 weeks. Each participant is required to complete the first 2 treatment cycles. After completing the first 2 induction treatment cycles (i.e., a maximum of 12 weeks of treatment), they will be considered to have fulfilled the main research objective of this study. After 2 cycles of induction treatment, the decision will be made by the investigators based on the specific clinical circumstances.

  • DrugBlinatumomabStudies of BlinatumomabBlinatumomab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Blinatumomab for Injection (Blincyto),Administration route: Intravenous infusion; Dose: 9 μg/day or 28 μg/day;Drug administration schedule: Each 6-week period constitutes a treatment cycle. During each cycle, the drug is administered for 4 weeks and then the drug is withheld for 2 weeks. Each participant is required to complete the first 2 treatment cycles. After completing the first 2 induction treatment cycles (i.e., a maximum of 12 weeks of treatment), they will be considered to have fulfilled the main research objective of this study. After 2 cycles of induction treatment, the decision will be made by the investigators based on the specific clinical circumstances.

    Also known as: Blincyto

06

What researchers measure

Primary outcomes

  1. Css

    Css(Steady-State Plasma Concentration)

    Time frame: Cycle 1(Cycle 1=28 days), Day 8, Day 14, Day 21, Day 28, Day 29

  2. AUC0-24,d1

    Area under the plasma concentration-time curve from 0 to 24 hours on Day 1 (AUC0-24,d1)

    Time frame: Cycle 1(Cycle 1=28 days), predose and up to 24 hourspost-dose

  3. CR/CRh

    Proportion of patients with Complete remission (CR) or complete remission with partial hematologic recovery(CRh)

    Time frame: End of Cycle 1 and up to (+7) days (Cycle 1=28 days); End of Cycle 2 and up to (+7) days (Cycle 2=28 days)

Secondary outcomes

  1. Incidence of Adverse Events

    Frequency, severity, and type of adverse events graded according to National CancerInstitute Common Terminology Criteria for Adverse Events (NCI CTCAE)Version (v) 6.0

    Time frame: Up to 35 days after last dose / prior to subsequent anti-tumor therapy / prior to HSCT, whichever occurs first

  2. Immunogenicity

    ADA(anti-drug antibody) and Nab(neutralizing antibody)

    Time frame: Cycle 1, predose and Day 29(Cycle 1=28 days); Cycle 2, Day 29(Cycle 2=28 days); or at the time of early participant withdrawal

  3. T1/2

    Plasma half-life

    Time frame: Cycle 1, predose and Day 1, Day 8, Day 14, Day 21, Day 28, Day 29(Cycle 1=28 days)

  4. CL

    CL(Clearance)

    Time frame: Cycle 1, predose and Day 1, Day 8, Day 14, Day 21, Day 28, Day 29(Cycle 1=28 days)

  5. Vz

    Vz(Terminal Apparent Volume of Distribution)

    Time frame: Cycle 1, predose and Day 1, Day 8, Day 14, Day 21, Day 28, Day 29(Cycle 1=28 days)

  6. fluctuation coefficient

    fluctuation coefficient

    Time frame: Cycle 1, predose and Day 1, Day 8, Day 14, Day 21, Day 28, Day 29(Cycle 1=28 days)

  7. CRR

    CRR is defined as proportion of participants who achieve CR(Complete remission)

    Time frame: End of Cycle 1 and up to (+7) days (Cycle 1=28 days); End of Cycle 2 and up to (+7) days (Cycle 2=28 days); Completion of long-term follow-up period.

  8. CRh

    Proportion of participants who achieve CRh(Complete Remission with Partial Hematological Recovery)

    Time frame: End of Cycle 1 and up to (+7) days (Cycle 1=28 days); End of Cycle 2 and up to (+7) days (Cycle 2=28 days); Completion of long-term follow-up period.

  9. CRi

    Proportion of participants who achieve CRi(Complete Remission with Incomplete Hematological Recovery)

    Time frame: End of Cycle 1 and up to (+7) days (Cycle 1=28 days); End of Cycle 2 and up to (+7) days (Cycle 2=28 days); Completion of long-term follow-up period.

  10. MLFS

    Proportion of participants who achieve MLFS (Morphologic Leukemia-Free State)

    Time frame: End of Cycle 1 and up to (+7) days (Cycle 1=28 days); End of Cycle 2 and up to (+7) days (Cycle 2=28 days); Completion of long-term follow-up period.

  11. ORR

    Overall response rate(ORR) is defined as the percentage of patients achieving complete remission (CR) or complete remission with

    Time frame: End of Cycle 1 and up to (+7) days (Cycle 1=28 days); End of Cycle 2 and up to (+7) days (Cycle 2=28 days); Completion of long-term follow-up period.

  12. DOR

    Duration of remission(DOR) is time from first confirmed CR, CRi, CRh, MLFS or PR to first disease relapse or death from any cause, calculated separately by each best response category. For participants converting from initial CRi/CRh to subsequent CR, DOR start date remains the date of initial CRi/CRh.

    Time frame: End of Cycle 1 and up to (+7) days (Cycle 1=28 days); End of Cycle 2 and up to (+7) days (Cycle 2=28 days); Completion of long-term follow-up period.

  13. Minimal Residual Disease(MRD) Negativity Rate

    Proportion of patients achieving MRD negativity

    Time frame: End of Cycle 1 and up to (+7) days (Cycle 1=28 days); End of Cycle 2 and up to (+7) days (Cycle 2=28 days); Completion of long-term follow-up period.

  14. EFS

    Event-Free Survival (EFS) is defined as the time interval from the date of first study drug administration to the earliest occurrence of any of the following events: treatment failure, disease relapse, or death from any cause. Treatment failure is defined as failure to achieve CR, CRh, CRi, or MLFS after treatment. Notably, participants with EFS event attributed to treatment failure will be assigned an EFS duration of 1 day.

    Time frame: End of Cycle 1 and up to (+7) days (Cycle 1=28 days); End of Cycle 2 and up to (+7) days (Cycle 2=28 days); Completion of long-term follow-up period.

  15. OS

    Overall Survival (OS)) is defined as the duration of time from treatment initiation until the participant's death due to any reason.

    Time frame: End of Cycle 1 and up to (+7) days (Cycle 1=28 days); End of Cycle 2 and up to (+7) days (Cycle 2=28 days); Completion of long-term follow-up period.

  16. Proportion of lymphocyte subsets

    Flow cytometry was used to determine the proportions of T cells (CD3+/CD4+/CD8+) and B cells (CD19+) to assess immune reconstitution status.

    Time frame: Cycle 1, predose and Day 1, Day 8 (Cycle 1=28 days)

  17. Serum concentration of IgG

    Serum IgG was quantitatively tested to assess B cell functional recovery.

    Time frame: Cycle 1, predose and Day 1, Day 8 (Cycle 1=28 days)

  18. Plasma concentration of cytokines

    Interleukin (IL)-2, IL-4, IL-6, IL-8, IL-10, IL-12, tumor necrosis factor alpha (TNF-α), interferon-γ (IFN-γ).

    Time frame: Cycle 1, predose and Day 1, Day 8 (Cycle 1=28 days)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared due to the sponsor's confidentiality policy and intellectual property restrictions.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Oct 2027, 14 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2026
First posted
Jul 23, 2026
StartEst.
Aug 9, 2026
Primary completionEst.
Oct 10, 2027
CompletionEst.
Oct 10, 2028
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07723911
Responsible party
Sponsor
First posted
Jul 23, 2026
Start date
Aug 9, 2026 (estimated)
Primary completion
Oct 10, 2027 (estimated)
Completion
Oct 10, 2028 (estimated)
Last update
Jul 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion